Domain Invest

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Saturday, 8 December 2007

Cat Ladies, Your Misunderstood Appendix, and "Lap Dance Science"

Posted on 11:30 by Unknown
We were going to throw this in with our weekend roundup, but we got to reading the "Year in Ideas" issue of The New York Times Magazine and by the time we got to the letter C in its alphabetized list of 2007's head-turning ideas, we realized it needed its own post. Dear readers, for the most part, we can't write about these kinds of things in IN VIVO. This is, in a nutshell, why we started blogging.

We confess to always enjoying this issue of the NYTM, though it would be interesting to go back to 2001, when they started doing this, to see how many of these ideas have panned out through the years.

Among the medical science related items (and up front, let us stress "related"), scientists writing in The Journal of Theoretical Biology have essentially rehabilitated the image of the good-for-nothing appendix. (Of course there's no ethical way to prove their theory that the appendix essentially repopulates the gut with beneficial bacteria following some sort of insult, but what the hell, why not. The appendix has been the afterthought of the GI tract for too long, we say.)

Researchers at UCLA are doing some rehabilitation of their own, and actually using an automated telephone system to help detect early signs of Alzheimer's. The Times notes that "the quiz also picks up behavioral warning signs including apathy, irritability and depression," though frankly we reckon if you don't exhibit those symptoms when you're using an automated telephone system, there's something amiss.

Moving on, here are a few other things we've learnt this afternoon:

Apparently roughly one-in-five Americans are infected with a parasite "that may migrate into their brains and alter their behavior in a way that — among other things — may leave them more likely to be eaten by cats." (Check out four of your friends, if they haven't smeared themselves with Tender Vittles, it's you.)

Want to know if your neighbors are on crack? Try a little Community Urinalysis.

It appears that ovulating strippers make more money than their colleagues.

Adding images of brainscans to even specious psychological claims makes the reports more believable to the layperson.

Finally: someone, please, convince us that writing about the biotech and pharmaceutical industries takes a lot of physical energy.

What's your favorite new idea of 2007? Do share, in the comments.
Email ThisBlogThis!Share to XShare to Facebook
Posted in | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Ventana Accepts $3.4 Billion
    Roche finally nabs its man. Or in this case, its diagnostics company. All it took was an extra $14.50 per share. From the companies' pre...
  • Merck: Embracing Externalization, From the Top Down
    Updated Below . One business magazine greeted the tenure of Dick Clark as Merck's new CEO in 2005 with the instruction to "say hel...
  • While You Were Coming Back
    It would be wrong for us not to mention the Red Sox in this space, the Boston nine having completed their three-game comback victory over th...
  • Unusual Suspects: If Pfizer Decides to Really Rattle the R&D Cages
    Yesterday, we listed a group of people -- we called them the usual suspects -- that we think Pfizer will try to woo if it ends up turning to...
  • Avandia and Rezulin: Parallels that Should Make GSK Nervous
    History doesn’t repeat itself but it does rhyme. That old Mark Twain saying must be making GlaxoSmithKline sweat as Avandia is starting to ...
  • Private Equity Goes Public
    One of the simplest metrics we have to measure interest in a company or industry is just how jammed the rooms are at the JP Morgan conferenc...
  • High Noon at Myogen
    Most VC meetings provide a feel-good story for the portfolio CEOs—usually a variation on the business resurrection theme. The Atlas Venture ...
  • While You Were Watching the Upsets
    This weekend we were in Cardiff for the Rugby World Cup quarterfinal between France and New Zealand, which saw France upsetting the favorite...
  • Deals of the Week: You Can't Always Get What You Want
    It's been a busy--and, for some, disheartening--week in biopharma land. Just three days after researchers disclosed that Vytorin , the h...
  • Sorry, I Still Don’t Get It
    Pfizer launched its first TV campaign for Exubera this past week in an attempt to breathe a little life into the stalled inhaled insulin br...

Categories

  • Abbott
  • activist shareholders
  • ADHD
  • advisory committees
  • alliances
  • Alnylam
  • Alzheimer's disease
  • Amgen
  • Andrew von Eschenbach
  • Andrew Witty
  • Astellas
  • AstraZeneca
  • Avandia
  • Avastin
  • Barack Obama
  • Barr
  • Bayer
  • Big Pharma
  • BIO
  • Biogen Idec
  • biologics
  • biosimilars
  • blogging
  • BMS
  • Boston Scientific
  • brand names
  • business development
  • business models
  • cancer vaccines
  • Carl Icahn
  • CBO
  • CDER
  • Celgene
  • Cephalon
  • China
  • clinical development
  • CMS
  • co-promotes
  • comparative effectiveness
  • conference
  • Congress
  • consumer genomics
  • corporate culture
  • corporate governance
  • corporate venture capital
  • CVS Caremark
  • Cytyc
  • David Kessler
  • deals of the week
  • debt financing
  • Diabetes
  • diagnostics
  • Dick Clark
  • drug approvals
  • drug delivery
  • drug discovery
  • drug eluting stents
  • Drug Pricing
  • drug safety
  • drug samples
  • DTC Advertising
  • e-health
  • Eisai
  • Elan
  • Eli Lilly
  • Emphasys
  • emphysema
  • Endo
  • epo
  • Euro-Biotech Forum
  • Exits
  • Exubera
  • FDA
  • FDA/CMS Summit
  • FDAAA
  • Film and TV
  • financing
  • FOBs
  • Forest Labs
  • Galvus
  • gene therapy
  • Genentech
  • General Electric
  • generics
  • Genzyme
  • Gleevec
  • Google
  • GSK
  • Guidant
  • haircuts
  • Happy Holidays
  • HCV
  • Headhunting
  • Health Care Reform
  • hedge funds
  • Henry Waxman
  • hGH
  • HHS
  • Hillary Clinton
  • Hologic
  • hostile takeovers
  • hypertension
  • ImClone
  • IMS Health
  • In vitro diagnostics
  • In3
  • India
  • insomnia
  • instrumentation
  • insulin
  • Inverness
  • IP
  • IPO
  • IPO pricing
  • Isis Pharmaceuticals
  • Israel
  • IT
  • JAMA
  • Januvia
  • Japan
  • John McCain
  • Johnson and Johnson
  • JP Morgan
  • LaMattina
  • lawsuits
  • layoffs
  • legislation
  • Life-Cycle Management
  • Lipitor
  • Lucentis
  • management succession
  • Mark McClellan
  • marketing
  • Martin Mackay
  • medical devices
  • Medicare
  • Medicare Part D
  • Medimmune
  • Medtech Insight
  • Medtronic
  • Merck
  • Merck-Serono
  • mergers and acquisitions
  • Michael McCaughan
  • Millennium
  • mmm beer
  • MRI
  • multiple sclerosis
  • music
  • nanotechnology
  • NEJM
  • new drug approvals
  • new funds
  • NICE
  • NicOx
  • NIH
  • Nobel Prize
  • Novartis
  • Novo Nordisk
  • Nycomed
  • off-label promotion
  • oncology
  • ophthalmology
  • Orthopedics
  • osteoporosis
  • OTC drugs
  • Out-Partnering
  • Oxycontin
  • pain
  • Part D
  • Patient Advocacy
  • PDUFA
  • personalized medicine
  • Pfizer
  • pharmacy benefits
  • PhRMA
  • politics
  • poll results
  • PR
  • prasugrel
  • Presidential Election
  • Press Release of the Week
  • Primary Care
  • private equity
  • Procter and Gamble
  • PSA
  • Purdue Pharma
  • rare diseases
  • reimbursement
  • research and development productivity
  • research and development strategies
  • reverse mergers
  • rimonabant
  • RiskMAP
  • RNAi
  • Roche
  • Roger Longman
  • royalties
  • sales forces
  • Sanofi-aventis
  • Schering-Plough
  • Science Matters
  • Sepracor
  • shameless self-promotion
  • share buybacks
  • Shire
  • Sirtris
  • Smith and Nephew
  • Solvay
  • SPACs
  • spec pharma
  • spin-outs
  • sports
  • Start-Up
  • statins
  • Steve Nissen
  • Stryker
  • Supreme Court
  • Takeda
  • Teva
  • Thanksgiving
  • The RPM Report
  • UCB
  • vaccines
  • Velcade
  • Ventana
  • venture capital
  • venture debt
  • Venture Round
  • Vertex
  • Vioxx
  • Vytorin
  • Wacky World of Generics
  • While You Were ...
  • Wyeth
  • Zetia
  • Zimmer
  • ZymoGenetics

Blog Archive

  • ►  2008 (76)
    • ►  February (25)
    • ►  January (51)
  • ▼  2007 (329)
    • ▼  December (32)
      • While We Weren't Blogging
      • Yule Blog: The Virtual Are Only Virtuous Thanks to...
      • While You Were Hanging Your Stockings By the Chimn...
      • Deals of the Week: The Christmas Edition
      • Paying the TLR Toll
      • A Note on Nanotech and Cancer Diagnostics
      • A bit techy yes...
      • An Ugly Divorce: Where Will David Kessler Land?
      • While You Were Snowed Under
      • Deals of the Week: Beyond Biogen
      • Biogen Idec and Carl Icant: A Report Card on Share...
      • The Hope and Challenge of Personalized HealthCare
      • The Lucentis/Avastin Investigation: “The Story is ...
      • So What's Next for Biogen?
      • Finding Common Ground on Off-Label Promotion
      • ENHANCE Interrogation Technique
      • Pfizer Supply Deal Ups Pressure on UK Price Cuts
      • REVA's a Keeper
      • Venturing to Washington II: Fleecing the Drug Indu...
      • Here's Looking at You, Barry
      • Drug Safety Alarm: "Something Big" Coming?
      • Venturing to Washington I: The Satanic Verses
      • While You Were at ASH
      • We Hardly Knew Ye, MGI
      • Cat Ladies, Your Misunderstood Appendix, and "Lap ...
      • Deals of the Week: It's the End of the World as We...
      • Pelikan Scoops up a Pouchful of Cash
      • "FDA Doesn't Have to Follow the Panel's Recommenda...
      • A Precision Move
      • A NICE New Business: Fee-for-Advice
      • Prasugrel: Lilly Tries to Stop the Bleeding (Part 2)
      • While You Were Dealing
    • ►  November (42)
    • ►  October (37)
    • ►  September (33)
    • ►  August (29)
    • ►  July (39)
    • ►  June (39)
    • ►  May (43)
    • ►  April (16)
    • ►  March (13)
    • ►  February (5)
    • ►  January (1)
  • ►  2006 (8)
    • ►  December (3)
    • ►  November (5)
Powered by Blogger.

About Me

Unknown
View my complete profile